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Abstract
In this study, the amounts and the fine structural characteristics of versican and decorin present in human colon adenocarcinomas (HCC)
were investigated and compared with those in human normal colon (HNC). HCC is characterized by significant increase in the amounts of
versican and decorin (13- and 8-fold in terms of protein, respectively). These two proteoglycans (PGs) were the predominant in HCC (86% of
total uronic acid). In HNC, versican and decorin contained both chondroitin sulfate/dermatan sulfate chains (CS/DS), with DS to be the
predominant one (90–93%). The molecular sizes (Mrs) estimated for DS and CS chains were 25–28 and 21–28 kDa, respectively. In CS/DS
chains isolated from both versican and decorin, 4-sulfated disaccharides accounted for 79–86% of total disaccharide units, respectively,
whereas lower amounts of 6- and non-sulfated units were also recorded. In contrast, the tumor-associated versican and decorin were of
smaller hydrodynamic size with lower glycosaminoglycan (GAG) content per PG molecule as compared with those found in HNC. In HCC,
both PGs contained mainly CS chains (up to 86%) and the Mrs of CS and DS chains were also found to be of smaller size (12 and 16 kDa,
respectively). The sulfation patterns of CS/DS chains from both PGs were also significantly different. They were composed mainly of 6-
sulfated disaccharides (63–70%), whereas 4-sulfated units accounted for 23–31%. A significant increase in the proportion of non-sulfated
disaccharides was also recorded. These findings indicate that the colon adenocarcinoma is characterized by a remarkable increase in the
concentration of versican and decorin. Furthermore, these PGs are significantly modified at the post-translational level, i.e. the type, length
and the sulfation pattern of their GAG chains. These specific structural alterations of versican and decorin may influence the biology of
cancer cells in HCC.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Proteoglycans (PGs) are macromolecules composed of a
core protein onto which variable number of glycosamino-
glycan (GAG) chains are covalently attached. They are key
bioactive molecules and are directly implicated in a large
variety of human diseases. Several studies indicated that
significant changes in PG content occur in the tumor stroma
of epithelial neoplasms and that these alterations support
tumor growth and invasion [1]. Colon carcinoma is a
common epithelial neoplasm, which is characterized by
increased levels of versican and decorin [2]. These PGs
contain chondroitin sulfate (CS)/dermatan sulfate (DS)
chains and are abnormally expressed in a wide variety of
malignant tumors. Versican is a member of the hyalectan
family and play important roles in forming hyaluronan (HA)-
rich matrix, which would provide cells with anti-adhesive
environment [3–5]. The deposition of versican in the tumor
stroma, particularly in HA-rich regions, probably supports
the cancer cell growth. The abnormal expression of versican
occurs as a consequence of hypomethylation of its control
genomic region and abrogation of versican expression by
antisense oligodeoxynucleotides can revert the malignant
phenotype. Decorin, a prototype member of the small
leucine-rich PG family [1,2,6], is emerging as a powerful
modulator of cell growth by affecting several key elements
including matrix assembly, binding of growth factors and
tyrosine kinase activity [7–9]. Decorin levels are suppressed
in most transformed cells [10], but markedly increased in the
peritumorous stroma of colon cancer [11]. The latter may
represent a natural biological response of the host cells to the
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invading neoplastic cells [12]. Many of the above biological
properties of these matrix PGs reside to the specific structural
characteristics of their GAG chains. Remarkable structural
alterations of GAG chains have been recorded in a variety of
neoplasms of the gastrointestinal tract and pancreas [13,14].
Particularly, poorly differentiated colon adenocarcinoma is
characterized by significant increase of HA-derived D-dis-
accharides and 6- and non-sulfated disaccharides as deter-
mined by high-performance capillary electrophoresis
(HPCE) [13].
The aim of this study was to determine in deep detail the
fine structural characteristics of the GAG moieties of versi-
can and decorin in human colon carcinoma (HCC). The
results reveal that the poorly differentiated colon adenocar-
cinoma is characterized by significant increase in the con-
centration of versican and decorin. In normal colon these
PGs contain primarily DS chains, whereas in colon carci-
noma they are mainly substituted with CS chains. Further-
more, in cancerous tissue, both GAGs exhibit smaller
molecular size and a quite different sulfation pattern.
2. Materials and methods
2.1. Chemicals
Sepharose CL-4B, CL-6B and DEAE-Sephacel were
obtained from Pharmacia Chemicals (Uppsala, Sweden).
Papain twice crystallized (EC 3.4.22.2), cetylpyridinium
chloride (CPC), chondroitinase ABC (EC 4.2.2.5), chon-
droitinase AC II (EC 4.2.2.4), heparin lyase II (heparitinase
II, no EC number), GAG standards and standard prepara-
tions of differently sulfated D-disaccharides from heparin
and heparan sulfate were from Sigma Chemical Co. (St.
Louis, MO, USA). Chondroitinase B (EC 4.2.2.5), heparin
lyases I and III (EC 4.2.2.7 and 4.2.2.8, respectively) and
standard preparations of variously sulfated D-disaccharides
from CS, DS, HA as well as monoclonal antibodies 2–B–1
against versican and 6–B–6 against decorin were purchased
from Seikagaku Kogyo. All chemicals used were of the best
commercially available grade.
2.2. Analytical methods
GAGs were detected in column fractions by the DMB
method [15] and uronic acid (UA) was determined by the
Bitter–Muir modified carbazole reaction [16]. Protein con-
tent was determined by the method of Bradford [17].
Unsaturated disaccharides released following treatment of
GAGs with chondroitinase ABC were determined by high-
performance liquid chromatography (HPLC) [18].
2.3. Tissue source—patients
Colon carcinomas were collected from patients (five
males/three females) aged 45–65 years, who underwent
colectomy for colon adenocarcinoma in the University
Hospital of Patras. Specimens were taken directly from
operating rooms. Specimens of normal colon, which
included mucosa and submucosa, were also collected from
the normal regions of the same patient. All specimens were
immediately stored at  70 jC. Pathological examination of
the neoplastic tissue showed poorly differentiated adenocar-
cinoma in six out of eight cases. The poorly differentiated
carcinomas were located in the descending and sigmoid
colon and were of stage C1 (two cases out of six) and C2
(four cases out of six) according to the modified Duke’s
classification of colon carcinoma. Normal tissue specimens
were free from specific histopathological evidence.
2.4. Extraction, isolation and characterization of versican
and decorin
The poorly differentiated carcinomas and the respective
normal specimens (n = 6) were finely diced and extracted
separately, by gentle shaking with 10 vol. of 4 M guanidine-
HCl–0.05 M sodium acetate, pH 5.8, containing protease
inhibitors for 24 h at 4 jC [19,20]. The extraction mixture
was filtered and the filtrate was retained. The residues were
re-extracted with 10 vol. of the same extracting solution.
The extracts were concentrated by ultrafiltration on a YM-
10 Amicon filter and then dialyzed against 0.15 M sodium
chloride containing the above described protease inhibitors.
Consequently, the PGs were isolated by precipitation with
CPC, extraction of the CPC-PGs complex with 2 M sodium
chloride and re-precipitation with ethanol [21].
PGs were dissolved in 4 M guanidine-HCl–0.05 M
sodium acetate pH 5.8, in the presence of protease inhibitors
and aliquots were obtained for chemical analyses. The
remainder were subjected to dissociative cesium chloride
density gradient ultracentrifugation (starting density = 1.42
g/ml). Ultracentrifugation was performed for 48 h at 10 jC,
in a Beckman L2-65B centrifuge with an 8 12 ml T 65
fixed angle rotor at 37,000 rpm. After centrifugation, the
tubes were frozen and cut into three fractions as follows:
bottom 3 ml (D1, density >1.53 g/ml), middle 6 ml (D2,
density 1.36–1.53 g/ml) and top 3 ml (D3, density < 1.36 g/
ml). The fractions were analyzed for uronic acid, hexosamine
and protein. The isolated proteoglycans of high buoyant
density (D1 fraction) and low buoyant density (D2 fraction)
were dialyzed against 10 M formamide–0.05 M sodium
acetate, pH 6.0, containing 0.2% Triton X-100 and all above
described inhibitors [22] and applied to a DEAE-Sephacel
microcolumn (3 ml) equilibrated with the same buffer. HA
were eluted by washing of the column with 3 vol. of the same
buffer containing 0.3 M NaCl. PGs were fractionated by
elution of the column with 10 vol. of a linear gradient
ranging from 0.3 to 0.85 M NaCl in formamide buffer.
HSPGs were eluted with f 0.4–0.5 M NaCl and were
completely separated from CS/DSPGs, which were eluted
with 0.55–0.7 M NaCl in each case. CS/DSPGs were pooled
as indicated by bars and concentrated.
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CS/DSPGs were further fractionated by gel filtration
chromatographies on analytical Sepharose CL-4B and -6B
columns (110 0.6 cm), equilibrated and eluted with 4 M
guanidine-HCl–0.15 M sodium acetate, pH 5.8. The aver-
age molecular weight (Mr) of the proteoglycans was esti-
mated using proteoglycan standards for calibrating the
columns [23].
Identification of PGs was performed by Western blotting.
PGs were electrophoresed in 4–20% (w/v) acrylamide
gradient gels, containing SDS (SDS-PAGE) according to
the method of Laemmli [24]. Separate gels were stained
with Coomassie R-250 and Toluidine blue. The electro-
phoresed samples were transferred to polyvinylidenedifluor-
ide membranes (Immobilon-P) at constant current 80 mA at
4 jC for 20 h in 0.05 M Tris–HCl, pH 8.3. The membranes
were washed with 0.14 M NaCl in 0.01 M phosphate buffer,
pH 7.2, containing 0.1% Tween 20 (PBS-T) and blocked
with 5% dry defatted milk in PBS-T. They were immersed
in antiserum against either versican (monoclonal antibody,
clone 2–B–1) [25,26], decorin (monoclonal antibody, clone
6–B–6) and biglycan (polyclonal antibody) [27], diluted
1:1000 in PBS-T and incubated for 60 min at room temper-
ature. The membranes were washed and incubated with
peroxidase-labelled secondary antibodies (rabbit anti-
mouse/goat anti-rabbit) diluted 1:2000 in PBS-T for 60
min at room temperature. The membranes were washed
and the immunoreacted bands were visualized by the
enhanced chemilumiscence technique (ECL, Amersham)
according to the instructions of the manufacturer.
2.5. Isolation and characterization of GAGs
Aliquots of isolated PGs were digested with papain and
the GAGs were released from remaining peptide fragments
by treatment with 0.05 M NaOH/1 M sodium borohydride at
45 jC for 48 h under vacuum [28,29]. Characterization and
quantitation of GAGs were performed following acetate
cellulose electrophoresis [30], gel filtration on analytical
columns of Sepharose CL-6B and HPLC analyses before
and after treatment with a mixture of heparin lyases I, II and
III and/or chondroitinases ABC and AC II [31]. Disacchar-
ide composition and sulfation pattern of GAGs were esti-
mated following digestion with chondroitinase ABC and
HPLC analysis [18]. Gel filtration of GAGs was performed
Fig. 1. Fractionation of NPGs-D1 and CPGs-D1 (A) and NPGs-D2 and CPGs-D2 (B) from normal colon (o) and colon carcinoma (.), respectively, by anion-
exchange chromatography on DEAE-Sephacel microcolumn (3 ml bed volume). The column was elute stepwise with 3 vol. of the formamide buffer described
in the text containing 0.3 M NaCl and 10 vol. of a NaCl linear gradient ranging from 0.3 to 0.85 M. Fractions of 0.5 ml were collected and aliquots were
precipitated by the addition of 4 vol. of ethanol. Precipitates were dissolved in distilled water and analyzed for their GAG content by the DMB method. (C)
SDS-PAGE (lanes 1 and 2) and immunoblot analyses (lanes 3 and 4) of CS/DSPGs isolated from NPGs-D1 (lanes 1 and 3) and CPGs-D1 (lanes 2 and 4). CS/
DSPGs were electrophoresed without any treatment in 4–20% gradient gels and they were stained with Toluidine blue (lanes 1 and 2). Immunostaining was
performed in CS/DSPGs which had been digested with chondroitinase ABC using the monoclonal antibody 2–B–1 against versican (lanes 3 and 4). (D) SDS-
PAGE (lanes 1 and 2) and immunoblot analyses (lanes 3–6) of CS/DSPGs isolated from NPGs-D2 (lanes 1, 3 and 4) and CPGs-D2 (lanes 2, 5 and 6). CS/
DSPGs were electrophoresed without any treatment in 4–20% gradient gels and they were stained with Toluidine blue (lanes 1 and 2). Immunostaining was
performed in CS/DSPGs before (lanes 3 and 5) and after digestion (lanes 4 and 6) with chondroitinase ABC using the monoclonal antibody 6–B–6 against
decorin. The figure indicates a representative case of normal (n= 6) and cancerous specimens (n= 6) examined.
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on analytical Sepharose CL-6B column (110 0.6 cm),
equilibrated and eluted with 0.5 M sodium acetate, pH
7.0. The Mrs of the CS and DS chains were estimated by
the construction of the secondary profile according to a
recent study [32], using CS molecular weight standards for
calibrating the column. In brief, the mixture of isolated CS/
DS was digested with chondroitinase B and the profile,
upon gel chromatography on Sepharose CL-6B, was com-
pared to that of the initial undigested sample. The absolute
amounts or percentage of uronic acid measured in each
fraction of the chromatographies before and after treatment
with chondroitinase B were subtracted, fraction by fraction,
and the differences were obtained. The positive differences
were used to construct the secondary profile, which repre-
sented the uronic acid content of the fractions removed after
the enzymatic digestion, i.e. the elution profile of intact DS
chains, and thus the size distribution of DS was obtained
and its Mr was calculated.
2.6. Statistical analysis
Statistical analysis was performed by the t-test using the
microcal origin software (version 3.2).
3. Results
3.1. Isolation and characterization of versican and decorin
The extracts of each specimen from normal colon and
colon carcinoma (n = 6) were analyzed separately for their
uronic acid contents. These analyses indicated that the
dissociative extraction of normal and cancerous specimens
removed up to 83–87% of total uronic acid in both tissues.
PGs from each specimen were isolated separately following
CPC and ethanol precipitation and further subjected to
equilibrium–density-gradient fractionation under dissocia-
tive conditions. The gradient was divided into three frac-
tions and the distribution of uronic acid and protein was
determined. The top fractions of buoyant density (D3,
P < 1.36 g/ml) from both normal and cancerous tissues
contained about 2% of total uronic acid and were not further
examined. The specimens of normal colon contained mainly
(87–91% of total uronic acid) PGs of high buoyant density
(NPGs-D1, P>1.53 g/ml) and a small proportion (7–11% of
total uronic acid) of PGs of low buoyant density (NPGs-D2,
1.36 <P < 1.53 g/ml). In colon carcinoma, the PGs of high
buoyant density (CPGs-D1) represented the 80–83% of total
uronic acid and those of low buoyant density PGs (CPGs-
D2) accounted for 15–18% of total uronic acid.
NPGs-D1 and CPGs-D1 were further fractionated by ion-
exchange chromatography on DEAE-Sephacel column. A
typical profile of these chromatographies is shown in Fig.
1A. The column was eluted with 10 vol. of a NaCl linear
gradient ranging from 0.3 to 0.85 M and two populations
were resolved in each case. The column recoveries exceeded
93% and the elution patterns were reproducible. As assessed
following treatments of the isolated populations with a
mixture of heparin lyases as well as with chondroitinases
ABC and AC II, and analyses by HPLC and cellulose
acetate electrophoresis, population I contained HSPGs,
whereas population II contained a mixture of CS/DSPGs
(Fig. 1A). Similarly to NPGs-D1 and CPGs-D1, PGs present
in fractions NPGs-D2 and CPGs-D2 were isolated following
ion-exchange chromatography. NPGs-D2 and CPGs-D2
fractions were chromatographed on DEAE-Sephacel col-
umn and only population II of CS/DSPGs, which was eluted
with 0.55–0.7 M NaCl, was recorded in each case (Fig. 1B).
The isolated CS/DSPGs were further analyzed by SDS-
PAGE and immunoblotting using specific antibodies against
several types of matrix CS/DSPGs. Analyses were per-
formed before or/and after they had been digested with
chondroitinase ABC. SDS-PAGE of intact populations
NPGs-D1 and CPGs-D1 showed the presence of a large
size population, which remained in the top of the stacking
gel (Fig. 1C, lanes 1 and 2). Immunoblotting following
treatment of the populations NPGs-D1 and CPGs-D1 with
chondroitinase ABC revealed the presence of two core
proteins with Mrs>215 kDa in each tissue specimen, which
Fig. 2. Gel chromatography of pooled versican (A) and decorin (B) isolated
from normal colon (o) and colon carcinoma (.), on Sepharose CL-4B and
Sepharose CL-6B (110 0.6 cm i.d.), respectively. The columns were
eluted with 4 M guanidine-HCl–0.15 M sodium acetate, pH 5.8, and
fractions of 0.9 ml were collected. Aliquots of the fractions were
precipitated by the addition of 4 vol. of ethanol, dissolved in distilled
water and analyzed by the DMB method.
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reacted only with the monoclonal antibody 2–B–1 against
versican (Fig. 1C, lanes 3 and 4). In the isolated popula-
tions, NPGs-D2 and CPGs-D2, the presence of a single
population with apparent molecular size (estimated using
protein standards) of f 100 kDa for NPGs-D1 and f 80
kDa for CPGs-D1 was identified by SDS-PAGE (Fig. 1D,
lanes 1 and 2). Immunoblot analyses of these populations
before and after treatment with chondroitinase ABC, using
specific antibodies for the matrix CS/DSPGs described in
Material and methods revealed the only presence of decorin
with a core protein of f 40 kDa in these populations (Fig.
1D, lanes 3–6).
Both versican and decorin present in each tissue speci-
men were quantitated in terms of uronic acid and protein
(Table 1). HCC was found to contain significantly increased
amounts of versican (13-fold, 620F 45 Ag of protein/g w/w
of tissue) in comparison to human normal colon (HNC)
(45F 7 Ag of protein/g w/w of tissue). Furthermore, the
ratio of uronic acid to protein in versican isolated from HCC
(0.4) was decreased 40% as compared to that from HNC
(0.65). Decorin amounts were also markedly increased in
colon carcinoma (8-fold, 413F 30 Ag of protein/g w/w of
tissue) in comparison to normal colon (48F 5 Ag of protein/
g w/w of tissue) and a 40% decrease in the ratio of uronic
acid to protein was also estimated in cancerous specimens
(0.25 in normal colon and 0.15 in colon carcinoma) (Table
1). The analyses indicated no significant intrabatch differ-
ences in the concentrations of versican and decorin between
the various normal and cancerous specimens examined as
shown by the low variability in each group. For this reason,
versican and decorin from each group were separately
pooled and further structural analyses were performed on
pooled versican and decorin from HNC and HCC.
Gel chromatography of versican contained in HNC and
HCC on a Sepharose CL-4B column revealed the presence
of a homogeneous population in each case with Kav values
of 0.31 (Mr of 800 kDa) and 0.38 (Mr of 580 kDa),
respectively (Fig. 2A). The respective chromatography of
decorin on Sepharose CL-6B column also revealed the
presence of homogenous populations in each case with
Kav of 0.27 for normal tissue (Mr of 80 kDa) and 0.35 for
colon carcinoma (Mr of 56 kDa) (Fig. 2B). These results
indicated a 30% decrease in the molecular mass of both
versican and decorin in HCC.
Fig. 3. Gel chromatography of CS/DS chains isolated from pooled versican (A) and (B) and decorin (C) and (D) from normal colon (A) and (C) and colon
carcinoma (B) and (D) on an analytical Sepharose CL-6B column (110 0.6 cm i.d.), before (.) and after (o) treatment with chondroitinase B. The column
was eluted with 0.5 M sodium acetate, pH 7.0. Fractions of 0.9 ml were collected and analyzed for their uronic acid content. (Insets) Secondary profile of DS
chains, obtained from the positive differences of uronic acid in each fraction of the sample before and after digestion with chondroitinase B.
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3.2. Characterization of GAG chains of versican and
decorin
In order to examine the composition and fine chemical
structures of GAG chains attached into versican and
decorin, they were released following papain digestion
and alkaline borohydride treatment. GAGs were then chro-
matographed on an analytical Sepharose CL-6B column
before and after exhaustive digestion with chondroitinase B,
an enzyme that is specific for the degradation of DS-type
sequences. The products of digestion were eluted close to
the Vt of the column. In versican and decorin isolated from
normal colon, the enzyme degraded significant amounts of
the mixture of CS/DS chains (about 90–93% of total uronic
acid), indicating the prominent presence of DS in both
versican (Fig. 3A) and decorin (Fig. 3C). A minor propor-
tion (about 7–10% of total uronic acid) of the sample,
which was resistant to degradation with chondroitinase B
represents CS chains (Fig. 3A and C, Table 1). In contrast to
normal tissue, the chondroitinase B degraded only minor
amounts of the mixture of CS/DS chains attached into
versican (Fig. 3B) and decorin (Fig. 3D) in HCC. In both
versican and decorin from cancerous tissue, CS is the
predominant GAG (86% of total uronic acid in versican
and 77% in decorin), whereas DS accounts for 14–23% of
total uronic acid, respectively (Table 1).
The CS chains isolated from versican and decorin from
HNC after digestion of CS/DS chains with chondroitinase B
were eluted as single peaks with Kav of 0.62 and 0.54
corresponding to Mrs of 21 and 28 kDa, respectively (Fig.
3A and C, Table 1). The CS chains isolated from both
versican and decorin from HCC were of smaller size (Mr of
12 kDa in both PGs) (Fig. 3B and D, Table 1). The
secondary profiles of DS present in versican and decorin
were constructed (Fig. 2A–D insets) as described in Mate-
rials and methods. From these secondary profiles, the Mrs of
DS chains were calculated. DS chains belonging to both
versican and decorin from HCC were of smaller molecular
size (Mr of 16 kDa) as compared to those from normal
tissues (Mr of 25 kDa for versican and 28 kDa for decorin)
(Fig. 3A–D insets, Table 1).
Analyses for the sulfation pattern of the GalGAG chains
are presented in Table 1. In versican and decorin isolated
from HNC, 4-sulfated disaccharides predominated (79–
86% of total disaccharides, respectively). Lower amounts
of 6-sulfated (18–12% of total disaccharides in versican and
decorin, respectively) and non-sulfated units (3–2%) were
also recorded in the normal tissue (Table 1). In contrast, in
HCC the sulfation patterns of both versican and decorin
were significantly altered. Particularly, the relative propor-
tions of 6-sulfated and non-sulfated disaccharides were
markedly increased in both versican and decorin and
accounted for 70–63% and 7–6% of total disaccharides,
respectively (Table 1).
4. Discussion
Previous studies [33,34] have demonstrated that HCC is
characterized by the increased production of a structurally
altered CS by the connective tissue surrounding the neo-
plastic cells. Other studies [11] have shown that HCC
contained increased levels of decorin-bearing CS chain, in
which the non- and 6-sulfated disaccharides are the pre-
dominant units, as detected by specific antibodies. The
abnormal expression of versican in the cancerous tissue
has been also demonstrated [11,35,36]. In a recent study, we
showed that the poorly differentiated colon adenocarcinoma
and other epithelial cancers are associated with specific
compositional and structural modifications of GAGs [13].
The goal of the present study was to examine in deep
detail the fine structural characteristics of GAGs attached on
the abnormal expressed PGs versican and decorin in human
colon cancer and to compare them with normal tissue.
Table 1
Structural characteristics of versican and decorin isolated from human normal colon and poorly differentiated colon adenocarcinoma
PGs composition Versican Decorin
Normal colon Colon carcinoma Normal colon Colon Carcinoma
Uronic acid 29F 4 248F 30 12F 3 62F 7
Protein 45F 7 620F 45 48F 5 413F 30
Uronic acid/protein (w/w) 0.65 0.40 0.25 0.15
Mr of PGs (kDa) 800 580 80 56
CSa 10 86 7 77
DSb 90 14 93 23
Mr of CS (kDa) 21 12 28 12
Mr of DS (kDa) 25 16 28 16
Non-sulfated disaccharidesc 3 7 2 6
4-Sulfated disaccharidesc 79 23 86 31
6-Sulfated disaccharidesc 18 70 12 63
The results are expressed as Ag/g wet weight of tissue. Values are the meansF S.D. of the normal colon specimens (n= 6) and colon carcinoma specimens
(n= 6) examined.
a Percentage composition estimated in the pooled versican and decorin. CS was estimated as the chondroitinase B resistant material.
b Percentage composition estimated in the pooled versican and decorin. DS was estimated as the chondroitinase B degradable material.
c Percentage composition estimated in the pooled versican and decorin.
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The results indicated that HNC contained versican and
decorin, which are primarily substituted with DS side
chains. HCC contained significantly elevated amounts of
versican (13-fold increase of protein amounts) and decorin
(8-fold increase of protein amounts). CS chains are the
major GAG attached in both PGs in HCC. The ratios of
uronic acid to protein for versican and decorin in the
diseased tissue (0.40 and 0.15, respectively) were markedly
decreased (f 40%) as compared to those of normal tissue
(0.65 and 0.25, respectively). Additionally, in colon carci-
noma, versican and decorin exhibited lower Mrs (f 30%)
than in normal colon. Both of these observations suggest a
poverty in GAG content of versican and decorin isolated
from colon carcinoma. This is probably due to the reduced
Mrs of CS and DS chains and not to fewer GAG chains per
core protein. Actually CS and DS found in cancerous tissue
exhibited a similar magnitude decrease (f 40–50%) in
their hydrodynamic sizes (12 and 16 kDa, respectively) in
comparison to those of normal colon (21–28 and 25–28
kDa, respectively). Further structural modifications, con-
cerning the sulfation patterns of both PGs, were also
documented. In normal tissue CS/DS chains of versican
and decorin are mainly composed of 4-sulfated disaccha-
rides, whereas the sulfation profile of CS/DS chains is
significant altered in the diseased tissue, showing a marked
increase in the proportions of non- and 6-sulfated disac-
charides. The latter one being the predominant type of
disaccharide units in colon carcinoma. The reduced propor-
tion of DS, a type of GAG containing iduronic acid, in the
cancerous tissue may be explained by the presence of 4-
sulfate units in low amounts in CS/DS chains, since the C-4
sulfation is a prerequisite for the C5 epimerase that converts
the glucuronic acid to iduronic acid [37].
Remarkable alterations in the biosynthesis of glycan
moieties of (glyco)proteins and PGs have been also docu-
mented during maturation of several tissues as well as in
the development of malignancies [38–40]. In colon adeno-
carcinoma, several genes involved in the biosynthesis of O-
glycans are abnormally expressed, resulting to the synthesis
of structural and antigenic altered O-glycans by cancer cells
[40]. The sulfation pattern of GAGs is also suggested as
key mediator of several biological events. It has been
proposed [41] that the increase in the ratio of 6-sulfated
chondroitin to 4-sulfated chondroitin represents a general
phenomenon that is occurred in immature tissues, which
containing proliferating and differentiated cells and it is
suggested to influence some developmentally significant
events such as cellular adhesion, migration and neurite
outgrowth [42,43]. As shown by recent studies, the type
and the sulfation patterns of versican and decorin present in
the extracellular matrix is of great importance for the
migration of the cells through the matrix. Perissinotto et
al. [44] demonstrated that versican promotes the migration
of neural crest cells, lining their migratory routes and this
function is mediated by both the core protein and the GAG
side chains. Versican purified from the migratory routes of
neural crest cells is primarily substituted with 6-sulfated
chondroitin. The substitution of versican with DS chains is
suggested to be responsible for the ‘repulsion-like’ effects
exerted on the migration of neural crest cell. Identical
effects have been also documented for aggrecan, the
homologous PG of versican, which inhibits the migration
of neural crest cells. In this inhibitory effect of aggrecan,
keratan sulfate (KS) side chains may play central role
[45,46]. Furthermore, Merle et al. [47] showed that decorin
inhibits the migration of MG-63 osteosarcoma cells and
this phenomenon is depended of both core protein and
GAG chain and is differentially mediated by its GAG side
chains. Particularly, it was demonstrated that decorin bear-
ing DS chain was 20-fold more effective in inhibiting
migration of cells than decorin bearing CS chains.
The above described observations suggest that the spe-
cific structural alterations of versican and decorin described
in this study may influence the biology of cancer cells in
colon carcinoma. The remarkable substitution of both PGs in
the stroma of colon carcinoma with CS chains and 6-sulfated
disaccharides may contribute to the growth, proliferation and
migration of cancer cells through a mechanism similar to that
observed in neural crest and osteosarcoma cells migration.
Further studies to demonstrate the functional relevance of the
alterations observed in the biosynthesis of versican and
decorin in colon carcinoma are under progress. It is becom-
ing important to clarify the possible relation of the modified
glycanation of the extracellular matrix PGs with the cancer
cells proliferation and migration.
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